Soon, on April 28 there will be M-Health Congress 2017. All of its speakers have already been listed, topics of their presentations have been announced. All we need is to acquaint you with the main moderator of the conference. Meet Andrey Perfiliev, co-founder and medical director at Atlas Biomedical Holding.
Andrey may be deservedly called one of the initiators of the development of personalized medicine in Russia. It is he who together with Atlas Holding founders actively promotes this direction among the professional community, as well as introduces personalized medicine tools in Atlas medical center. Learn more about his activities from Andrey’s interview: M-Health Congress press office has talked with him and found many interesting details.
1. Tell us please about the technologies used in your holding. Why are they unique?
Atlas is a biomedical holding. We have technological departments that develop services in the field of human genome analysis, genetics of intestinal microbiota, oncogenetics. We have also opened a medical center, where we use our developments to provide personalized treatment to patients. In this respect, Atlas medical center is the first facility of personalized medicine in Russia, since it can apply the most advanced genomic technologies.
2. How do you think, what are the prospects of personalized medicine in Russia?
Very high, first of all in terms of the quality of scientific potential. In this regard, staff and equipment of many scientific laboratories are professional and high-quality. But, of course, this is not enough; huge efforts and particular actions are necessary from both the state and business community. In many countries, for example the USA, Canada, France, China, large-scale national programs have been adopted to introduce personalized medicine. They include huge funding and large-scale involvement of the business community.
3. Can we expect a full-fledge digital healthcare system to appear in Russia this year? If no, why?
Currently, no one can say for sure that a full-fledged digital healthcare system exists anywhere, in fact. It is a very large, complex and expensive issue, and when addressing it, difficulties occur inevitably, even in developed countries. For example, the UK have invested 12 billion pounds in the creation of a national electronic medical record, but later on the project was declared invalid.
Therefore, in my opinion, it is too early to talk about the emergence of digital healthcare in the near future. But undoubtedly, the foundation of this process has already been laid, and it will determine the future of the entire medicine in general.
4. Development of which sectors of telemedicine and technologies is more topical today?
First of all, I would say monitoring of patients with chronic diseases and supporting patients after discharge from the hospital. Undoubtedly, telemedicine can be applied at almost all stages of medical care, but so far, due to legislative and technological limitations, those areas where dynamic patient control and no initial diagnosis is required will be developed.
5. Which technologies are the most popular among investors?
In fact, now investors are investing more in telemedicine platforms, which are focused on different models. At the same time, there are also highly specialized projects, for example, support systems for patients with mental disorders or some neurological diseases, but the number of such niche projects is low.
6. How does the state support the development of telemedicine in general and young developers in particular? Are there any special programs, grants, etc.?
The Russian budget allocates about 5 billion rubles annually for informational support of healthcare. Interdisciplinary working groups have been created, and there have been profile associations for many years. Recently, a law on telemedicine was introduced in the State Duma, which, in fact, became the first law for the digital medicine industry, and this is also a great victory. Programs and grants are now mostly provided to R&Ds, for example, Skolkovo in a profile cluster. Some venture capital funds and even large corporations are now financing projects in the field of digital medicine as well. For example, recently, Sberbank has announced the purchase of DocDoc, a service for making an appointment with doctor, which is also a good signal for the market.
7. How do you think, how important are such events as M-Health Congress for the development of the industry?
Such activities are very useful for the industry. Firstly, we get a general idea of the market participants and projects. Secondly, dialogue between industry participants is important, and we see it during similar events.
8. What are your expectation from M-Health Congress 2017?
First of all, I’m expecting quality discussion between invited speakers. M-Health Congress 2017 has attracted leaders of the digital medicine market, and we will be able to hear first-hand about the most topical issues of healthcare informational support and development trends. We will learn how startups, successful companies and large corporations see the development of digital medicine.
Summarizing everything said by Andrey, we’d like to note that M-Health Congress 2017 will discuss the most urgent and acute problems of modern telemedicine. This year the event will bring together absolutely all representatives of the industry, including patients and public medical organizations. Thus, you will be able to hear different points of view and understand the attitude of different participants of the healthcare system.
The conference will be held on April 28 in Mercure Hotel, Moscow. For participation, please register.